vs
FrontView REIT, Inc.（FVR）与Verastem, Inc.（VSTM）财务数据对比。点击上方公司名可切换其他公司
FrontView REIT, Inc.的季度营收约是Verastem, Inc.的1.6倍（$18.2M vs $11.2M），FrontView REIT, Inc.净利率更高（2.2% vs -876.3%，领先878.5%）
Verastem, Inc.以Verastem Oncology品牌开展业务，是一家总部位于美国马萨诸塞州波士顿的制药企业，专注于开发抗癌治疗药物，该公司成立于波士顿，同时是纳斯达克生物技术指数成分股之一。
FVR vs VSTM — 直观对比
营收规模更大
FVR
是对方的1.6倍
$11.2M
净利率更高
FVR
高出878.5%
-876.3%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.2M | $11.2M |
| 净利润 | $400.0K | $-98.5M |
| 毛利率 | — | — |
| 营业利润率 | 24.9% | -362.2% |
| 净利率 | 2.2% | -876.3% |
| 营收同比 | 12.0% | — |
| 净利润同比 | — | -311.1% |
| 每股收益（稀释后） | — | $-1.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FVRVSTM
| Q1 26 | $18.2M | — | ||
| Q4 25 | $16.5M | — | ||
| Q3 25 | $16.8M | $11.2M | ||
| Q2 25 | $17.6M | $2.1M | ||
| Q1 25 | $16.2M | — | ||
| Q3 24 | $14.5M | $0 | ||
| Q2 24 | — | $10.0M |
净利润FVRVSTM
| Q1 26 | $400.0K | — | ||
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $4.0M | $-98.5M | ||
| Q2 25 | $-2.9M | $-25.9M | ||
| Q1 25 | $-833.0K | — | ||
| Q3 24 | $-2.4M | $-24.0M | ||
| Q2 24 | — | $-8.3M |
营业利润率FVRVSTM
| Q1 26 | 24.9% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -362.2% | ||
| Q2 25 | — | -2047.9% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -182.8% |
净利率FVRVSTM
| Q1 26 | 2.2% | — | ||
| Q4 25 | -24.9% | — | ||
| Q3 25 | 23.9% | -876.3% | ||
| Q2 25 | -16.5% | -1213.6% | ||
| Q1 25 | -5.1% | — | ||
| Q3 24 | -16.7% | — | ||
| Q2 24 | — | -82.6% |
每股收益（稀释后）FVRVSTM
| Q1 26 | — | — | ||
| Q4 25 | $-0.19 | — | ||
| Q3 25 | $0.19 | $-1.35 | ||
| Q2 25 | $-0.16 | $-0.62 | ||
| Q1 25 | $-0.06 | — | ||
| Q3 24 | — | $-0.60 | ||
| Q2 24 | — | $-0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.3M | $137.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $514.2M | $-15.5M |
| 总资产 | $869.8M | $176.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FVRVSTM
| Q1 26 | $9.3M | — | ||
| Q4 25 | $13.5M | — | ||
| Q3 25 | $19.6M | $137.7M | ||
| Q2 25 | $8.4M | $164.3M | ||
| Q1 25 | $3.3M | — | ||
| Q3 24 | — | $113.2M | ||
| Q2 24 | — | $83.4M |
总债务FVRVSTM
| Q1 26 | — | — | ||
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q3 24 | — | $40.5M | ||
| Q2 24 | — | $40.3M |
股东权益FVRVSTM
| Q1 26 | $514.2M | — | ||
| Q4 25 | $391.2M | — | ||
| Q3 25 | $385.2M | $-15.5M | ||
| Q2 25 | $369.9M | $36.1M | ||
| Q1 25 | $324.7M | — | ||
| Q3 24 | $1.0K | $11.1M | ||
| Q2 24 | — | $18.9M |
总资产FVRVSTM
| Q1 26 | $869.8M | — | ||
| Q4 25 | $854.4M | — | ||
| Q3 25 | $846.8M | $176.9M | ||
| Q2 25 | $856.5M | $196.3M | ||
| Q1 25 | $860.8M | — | ||
| Q3 24 | $1.0K | $126.4M | ||
| Q2 24 | — | $105.7M |
负债/权益比FVRVSTM
| Q1 26 | — | — | ||
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q3 24 | — | 3.66× | ||
| Q2 24 | — | 2.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-36.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FVRVSTM
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | — | ||
| Q3 25 | $8.3M | $-36.2M | ||
| Q2 25 | $9.3M | $-32.7M | ||
| Q1 25 | $8.1M | — | ||
| Q3 24 | — | $-23.8M | ||
| Q2 24 | — | $-27.6M |
自由现金流FVRVSTM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-27.6M |
自由现金流率FVRVSTM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -275.8% |
资本支出强度FVRVSTM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% |
现金转化率FVRVSTM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
